Experts engage in discussion on patient profiles to review updated treatment approaches and sequencing in patients with HER2-positive metastatic breast cancer.
April 1st 2022
Comprehensive insight on therapeutic classes and agents approved in the setting of HER2+ metastatic breast cancer, with a specific focus on how these therapies fit into current treatment strategies.
Shared insight on the optimal sequencing of therapeutic agents for patients undergoing treatment for HER2+ metastatic breast cancer.
April 8th 2022
Before moving on to the patient profiles, expert panelists review recent clinical trial data that have impacted treatment selection and sequencing in HER2+ metastatic breast cancer.
Centering discussion on a patient profile of HER2+ metastatic breast cancer, experts elucidate frontline therapy selection in this setting.
April 15th 2022
Expert perspectives on the selection of second-line therapy when patients progress with HER2+ metastatic breast cancer.
Shared insights on the use of therapies as a patient progresses with HER2+ metastatic breast cancer, which includes sequencing through T-DM1 [trastuzumab emtansine], tucatinib/capecitabine/trastuzumab, and trastuzumab deruxtecan.
April 22nd 2022
Experts discuss the use of frontline therapy in patients with triple-positive metastatic breast cancer.
Expert perspectives on second-line treatment options available for patients who progress with triple-positive metastatic breast cancer.
April 29th 2022
Before closing out their discussion on the second patient profile, experts review third-line treatment selection for triple-positive metastatic breast cancer.
A summary of sequencing therapy in the HER2+ metastatic breast cancer treatment paradigm followed by excitement for novel therapies under investigation.
May 19th 2022
Breast medical oncologist, Tiffany Traina, MD, shares a clinical scenario of a patient with HER2+ metastatic breast cancer and discusses her treatment approach in the neoadjuvant, adjuvant, and metastatic settings.
Expert perspectives on the use of trastuzumab deruxtecan in a patient with HER2+ metastatic breast cancer.